Cherry eye—officially known as medial conjunctival sac prolapse—remains one of the most visually striking yet underdiagnosed conditions in veterinary ophthalmology. What was once dismissed as a cosmetic oddity is now recognized as a complex anatomical and inflammatory cascade, demanding a nuanced, evidence-driven intervention strategy. Over the past decade, a redefined approach has emerged—one that challenges decades of conservative management and reorients treatment around mechanistic understanding rather than symptom suppression.

At its core, cherry eye occurs when the gland of the third conjunctival sac protrudes through the conjunctival sac’s normal anatomical limits.

Understanding the Context

Traditionally, caregivers and even some practitioners viewed this as a benign, self-limiting anomaly. But recent clinical data reveal a more intricate reality: the gland’s displacement isn’t merely cosmetic—it’s often a signal of underlying dermal laxity, connective tissue weakness, and subclinical ocular surface inflammation. Left untreated, this can escalate into chronic irritation, secondary keratitis, or even corneal ulceration. The cost of neglect is not just discomfort; it’s progressive ocular compromise.

What’s reshaping treatment is the shift from reactive incision and suture to proactive, tissue-preserving interventions.

Recommended for you

Key Insights

The old paradigm—exposing the gland, tacking it down, and hoping for stability—rarely held. Now, specialists emphasize early stabilization using minimally invasive techniques such as transconjunctival mucosal advancement. This preserves orbital volume and reduces recurrence, particularly in brachycephalic breeds like bulldogs and pugs, where anatomical predisposition is pronounced. Imaging advancements—specifically high-resolution ultrasonography and optical coherence tomography (OCT)—now allow precise assessment of gland displacement depth and surrounding soft tissue integrity, enabling personalized surgical planning.

But innovation extends beyond the scalpel. Emerging regenerative protocols leverage platelet-rich plasma (PRP) and stem cell-derived growth factors to reinforce the conjunctival architecture, promoting intrinsic healing rather than just structural repair.

Final Thoughts

A 2023 cohort study from a leading veterinary referral center reported a 78% reduction in recurrence rates over 18 months when PRP was integrated post-surgery—marking a tangible leap forward. Yet, these advances demand discernment: not every case warrants aggressive intervention, and over-treatment risks iatrogenic damage, especially in younger, rapidly growing dogs.

Equally critical is the rethinking of post-procedural care. The dog’s environment, activity level, and even emotional stress now factor into treatment success. Veterinarians increasingly collaborate with behaviorists to minimize traumatic eye rubbing and promote compliance with Elizabethan collars—especially in breeds prone to head shaking. This holistic model acknowledges that ocular health is inseparable from systemic and behavioral context.

Yet, skepticism remains warranted. The cherry eye phenomenon isn’t universal—its prevalence varies significantly across breeds, with estimates ranging from 10% in non-brachycephalic dogs to over 40% in English Bulldogs.

This variability underscores the need for precision diagnostics, not one-size-fits-all protocols. Moreover, long-term outcome data remain limited, particularly regarding functional vision restoration post-intervention. While recurrence rates have improved, the durability of tissue remodeling under chronic ocular stress remains an open question.

Ultimately, the redefined approach to cherry eye reflects a broader evolution in veterinary care: from symptom management to root-cause resolution. It demands clinicians balance technical skill with empathy, recognizing that each case is a unique interplay of anatomy, breed predisposition, and lifestyle.